Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07335211

Enrollment

206

Registered

2026-01-13

Start date

2026-01-31

Completion date

2027-12-31

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Primary Open Angle Glaucoma (POAG)

Brief summary

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Interventions

DRUGHUC3-637

Ophthalmic solution instilled directly into the eye (topical ocular administration)

DRUGHUC3-637-R

Ophthalmic solution instilled directly into the eye (topical ocular administration)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults aged 19 years and older * Participants diagnosed with POAG or OH * Have fully explained and understood the study and have voluntarily given written informed consent.

Exclusion criteria

* Acute or chronic angle-closure glaucoma * Congenital glaucoma, secondary glaucoma (open-angle glaucoma)

Design outcomes

Primary

Measure	Time frame
Mean change in diurnal IOP	12 week

Countries

South Korea

Contacts

Primary ContactRang Lee

rlee@huons.com07074926091

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026